MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company developing treatments for inflammatory diseases, filed an 8-K with the SEC on October 4, 2021, in connection with its proposed business combination with HLXA, a blank-check company that completed its IPO in 2021. The transaction was structured to bring MoonLake into the public markets on Nasdaq, where it subsequently traded under the ticker MLTX. MoonLake's pipeline centers on sonelokimab, an investigational IL-17A/F nanobody being evaluated across indications including psoriatic arthritis and hidradenitis suppurativa, placing the deal within the healthcare and biotechnology sector of the SPAC market. Sign up for SpacDesk to access the full data profile, deal timeline, and filing history for HLXA.